Recursion ended Q2 2025 with $533M in cash, a 35% reduction in expected cash burn by 2026 versus 2024, and reaffirmed guidance for over $100M in partnership inflows by end of 2026. The company ...
Recursion Pharmaceuticals, Inc. (RXRX), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/10-K filing), reported ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 5,540 calls trading, 2x expected, and implied vol increasing over 2 points to 75.26%. Jan-27 5 calls and Nov-24 8 calls are the ...
Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end cash. Management ...
Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I am really excited to welcome you to our first ever Learnings Call here at Recursion. So what is a learnings call and why are we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results